A method for calibrating at least one analytic device with repeated hardware components is disclosed and comprises providing at least one calibrator sample i having a known target value of a concentration of at least one analyte; at least one measuring step, wherein the measuring step comprises conducting at least one measurement on the calibrator sample using the analytic device, wherein at least one detector signal s.sub.ijk is acquired; at least one calibration step, wherein a relationship between the detector signal and the concentration of the analyte and/or between the detector signal and a theoretical signal value is determined, wherein the calibration step comprises providing at least one parametrized function; determining calibration values by conducting a calibration based on the parametrized function; and determining an analysis function on basis of an inverse of the parametrized function and the determined calibration values.

The present invention provides methods for analyzing a target compound from a biological sample. In one aspect, a method for analyzing a target compound in a biological sample can comprise delivering a biological sample through an affinity column, the affinity column having a binding ligand coupled to a stationary structural support, wherein the affinity column has a high density of the binding ligand per the stationary structural support and wherein the binding ligand has been preselected to cause weak affinity separation zonal retardation of the target compound from the biological sample forming a target compound fraction and a biological sample fraction and detecting the target compound by mass spectrometry.

The present invention relates to a disease-specific metabolite profile, and particularly to a biomarker composition obtained by screening from urine-specific metabolite profiles of coronary heart disease subjects. The present invention also relates to a use of the biomarker compositions in risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease, and to a method for risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease. The biomarker composition as provided by the present invention can be used for early diagnosis of coronary heart disease and has high sensitivity, good specificity and good application prospects.

The disclosure provides methods for determining liver fibrosis development, risk and prognosis.

An analytical device includes: a first acceleration unit including a first acceleration electrode to which a pulse voltage for accelerating ions is applied; a flight tube; a second acceleration unit that is arranged between the first acceleration unit and the flight tube, and includes a second acceleration electrode to which a voltage for accelerating the ions is applied; an ion detector that detects the ions; and a capacitance adjustment unit that causes adjustment of a capacitance between at least one set of electrodes among a plurality of electrodes arranged in the first acceleration unit, the second acceleration unit, and a flight tube.

A method evaluates a quality of a dephosphorylation reagent, the method including the steps of: providing a dephosphorylation reagent containing an alkaline phosphatase and a peptide fragment derived from the alkaline phosphatase; and evaluating the dephosphorylation reagent as having a high quality if a content ratio of the peptide fragment to the alkaline phosphatase is a predetermined reference value or less.

MRM triggered MRM, where the triggered MRM transitions make use of mobility device parameter values for the same compound, is performed. A plurality of primary MRM transitions are received and stored together with a mobility device parameter value for each transition as an MRM cycle list. Control information instructs a mobility device and a mass spectrometer to interrogate each MRM transition on the MRM cycle list within an MRM cycle of the mass spectrometer. If a product ion intensity value of an MRM transition exceeds a threshold value for a primary MRM transition, a plurality of secondary MRM transitions of the primary MRM transition with different mobility device parameter values are added to the MRM cycle list. The intensities of the measured secondary MRM transitions provide information on the optimum mobility device parameter for each compound.

A device is described for generating ionized molecules for analysis in a mass spectrometer. The device includes: a solid substrate having one or more edges and a coated area that is coated with an extraction phase comprising an extraction polymer. The solid substrate may have at least two edges that meet at an angle from about 8° to about 180°. Mass spectrometry systems that include such a device are also described. Methods of analyzing a molecule previously extracted from a sample onto the device are also described.

A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target plant material; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said plant material.

Described herein are passive samplers, making of such samplers, and methods of use. In an example embodiment, a passive sampling membrane comprises, for example, a continuous mesoporous sequestration media having a sequestration phase and a support membrane configured to support the sequestration phase. The sequestration phase may include a hydrophobic region and a hydrophilic region. The continuous mesoporous sequestration media may be configured to simultaneously sequester polar and non-polar organic substances.